STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title	Page 1
		or the abstract	
		(b) Provide in the abstract an informative and balanced summary of	Page 2
		what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 3
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 3
Methods		1	8 -
Study design	4	Present key elements of study design early in the paper	Page 4
Setting	5	Describe the setting, locations, and relevant dates, including periods of	Setting/location,
Setting	3	recruitment, exposure, follow-up, and data collection	recruitment:
		recruitment, exposure, follow-up, and data confection	
			Page 4 Outcome dates:
			Page 5
			Exposure dates:
			Page 5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	Page 4
x7 ' 11		selection of participants	D
Variables	7	Clearly define all outcomes, exposures, predictors, potential	Outcomes: Pages 5
		confounders, and effect modifiers. Give diagnostic criteria, if	Exposures: Page 5-
		applicable	6, 20
			Predictors/potentia
			confounders: Pages
			5-6. 20-22
Data sources/	8*	For each variable of interest, give sources of data and details of	Page 4-5
measurement		methods of assessment (measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	Page 6
Study size	10	Explain how the study size was arrived at	Page 4, 6-7, 15
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	NA
		applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	Page 6
		confounding	
		(b) Describe any methods used to examine subgroups and interactions	Page 6-7
		(c) Explain how missing data were addressed	Page 6-7
		(d) If applicable, describe analytical methods taking account of	NA
		sampling strategy	
		(e) Describe any sensitivity analyses	Page 7
		<u> </u>	
Results			1
Results Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	Page 7. 15
Results Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible.	Page 7, 15
	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 7, 15

		(c) Consider use of a flow diagram	Page 15
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical,	Page 16 Table 1
		social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable	Page 6, 15
		of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	Page 16 Table 1
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	Pages 7-9
		estimates and their precision (eg, 95% confidence interval). Make clear	Page 17 Table 2
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were	Page 16 Table 1
		categorized	
		(c) If relevant, consider translating estimates of relative risk into	NA
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and	Page 9, 19, 23, 24
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	Pages 9-10
Limitations	19	Discuss limitations of the study, taking into account sources of	Pages 11-12
		potential bias or imprecision. Discuss both direction and magnitude of	
		any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	Page 9-12
		limitations, multiplicity of analyses, results from similar studies, and	
		other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 11-12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present	Page 12-13
		study and, if applicable, for the original study on which the present	
		article is based	

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.